infodive radiation oncology model s high-level overview
TRANSCRIPT
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
InfoDive®
Radiation Oncology Model
High-level OverviewNovember 9th, 2021
Presenters:
Cass Schaedig, Vice President, Provider Analytics
Cindy Dunn, RN, FACMPE, Support and Special Projects
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Disclaimer
• Information presented is done solely for informational and educational purposes
• Information should not be relied upon for purposes of regulatory compliance or
as a guarantee for increased revenues or practice successes or failures
• Information provided herein does not constitute and should not substitute for
legal advice; Practice should consult with Practice’s own legal and regulatory
counsel regarding all applicable legal and regulatory requirements
• The sample report has blinded data and provider identifiers have been given
fictitious IDs and names
11
/09
/20
21
Con
fid
en
tia
l2
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Agenda
• Radiation Oncology Model
• Participants
• Quality Measures
• Coding and Billing
• Simulation Reports within InfoDive
11
/09
/20
21
3C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Radiation Oncology (RO) Participants
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• Prospective, episode-based payment model
• RT providers will be paid predetermined rate per cancer type for 90-day episode of treatment, for included RT
services
• Mandatory participation from RT providers and RT suppliers that furnish RT services within randomly
selected Core-Based Statistical Areas (CBSAs)
• 5-year model - Begins January 1, 2022 and ends December 31, 2026
• CBSAs selected for RO Model contain approximately 30% of all eligible Medicare fee-for-service
(FFS) RT episodes nationally
• ZIP Code look-up tool, contains all five-digit ZIP Codes linked to selected CBSAs, available on RO
Model website
• Handout
Radiation Oncology Model1
1/0
9/2
02
15
Con
fid
en
tia
l
https://public-inspection.federalregister.gov/2021-23993.pdf
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• CMS adopted extreme and uncontrollable circumstances (EUC) policy that allows it to adjust model
performance periods, reporting requirements, and/or payment methodology when necessary
− CMS finalized its proposal to adopt EUC policy based on ongoing COVID-19 public health
emergency
• Unless HHS Secretary terminates his renewal of the COVID-19 PHE prior to January 1, 2022,
CMS intends to invoke provisions of EUC policy on January 1, 2022
• Specific RO Model flexibilities intended for PY 1 (January 1, 2022, through December 31, 2022) are
indicated by UPDATE in slide deck
• Additional information regarding implementation of these changes will be provided to RO participants
by CMS via upcoming learning events and materials
− Monitor Radiation Oncology website
Radiation Oncology Model1
1/0
9/2
02
16
Con
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
RO Model Participant Exclusions
− Exclude any PGP, freestanding radiation therapy center, or HOPD that furnishes RT
• Only in Maryland
• Only in Vermont
• Only in United States (U.S.) Territories
• Classified as:
− Ambulatory Surgical Center (ASC)
− Critical Access Hospital (CAH)
− Prospective Payment System (PPS) exempt cancer hospital
− Participates in or is identified by CMS as eligible to participate in the Pennsylvania Rural
Health Model (PARHM)
Radiation Oncology Model1
1/0
9/2
02
17
Con
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
3 types of participants
• Professional participant - Medicare-enrolled physician group practice identified by single Taxpayer
Identification Number (TIN) that furnishes only professional component of an RO episode
• Technical participant - Medicare-enrolled hospital outpatient department or freestanding radiation therapy
center, identified by single CMS Certification Number (CCN) or TIN, which furnishes only the technical
component of RO episode
• Dual participant - RO participant that furnishes both professional component and technical component of
RT services of RO episode through freestanding radiation therapy center, identified by single TIN
Opt-Out
• Any eligible RO participant can opt out of the RO Model on an annual basis if they furnish < 20 episodes
across all selected CBSAs in calendar year that is two years prior to the start of the PY
Radiation Oncology Model1
1/0
9/2
02
18
Con
fid
en
tia
l
https://innovation.cms.gov/innovation-models/radiation-oncology-model
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Radiation Oncology Model1
1/0
9/2
02
19
Con
fid
en
tia
l
All RO participants must:• Meet applicable state and federal licensure and certification requirements
• Submit claims, under existing Medicare claims systems in accordance with RO Model billing
instructions as described in final rule
• Submit claims in accordance with RO Model guidance for purposes of episode payment, submit
encounter data (“no-pay” claims) for all RT services furnished during episode for purposes of
reconciliation, monitoring, and evaluation
Technical participants and Dual participants must:• At such times and in way specified on RO Administrative Portal, annually attest to active
participation with an Agency for Healthcare Research and Quality-listed patient safety
organization
Professional participants and Dual participants must:• Discuss goals of care with RO beneficiaries before initiating treatment, and inform them whether
treatment intent is curative or palliative
• Adhere to nationally recognized, evidence-based clinical treatment guidelines when appropriate
or, alternatively, document in medical record extent of and rationale for any departure from
these guidelines
UPDATE:
Requirement that
participants actively
engage with an
AHRQ-listed patient
safety organization
(PSO) will be optional
in PY1 (2022)
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Radiation Oncology Model1
1/0
9/2
02
11
0C
on
fid
en
tia
l
Professional participants and Dual participants must:• Provide written notice of participation in RO Model to each RO beneficiary during treatment planning
• Handout - RO Beneficiary Letter
• Assess and document tumor, node, and metastasis cancer stage for cancer diagnosis, and
performance status as quantitative measure determined by physician
• Send treatment summary to each RO beneficiary’s referring physician within 3 months of end of
treatment
• Submit beneficiary data to RO Administrative Portal within 30 days for beneficiaries that opt out of
sharing claims data
As part of criteria to be an Advanced Alternative Payment Model:• Use Certified Electronic Health Record Technology (CEHRT) throughout performance year in
manner sufficient to meet applicable requirements of the Advanced Alternative Payment Model
criteria
• Attest annually to use of CEHRT within 30 days of start of each performance year
• Perform and document peer review (e.g., perform an audit and provide feedback on treatment
plans)
• See RO FAQ titled “What are the requirements for the peer review process?”
UPDATE:
Peer Review
(audit and
feedback) on
treatment plans
will be optional
in PY1 (2022)
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Radiation Oncology Administrative Portal (ROAP)
• Online platform used to track RO participant information and to allow users to access and review organizational data; update participant information and contacts
• See ROAP User Manual
RO Model Secure Data Portal
• Platform via which RO participants have opportunity to request different types of files from CMS, including: beneficiary line-level claims data, episode-level data, participant-level data, as well as submit quality measures and clinical data
• See RO Model Secure Data Portal User Manual
RO Connect
• Use this site for sharing documents, participating in online discussions, and receiving updates about RO Model activities, etc.
• Sign-up for Connect on ROAP site
Radiation Oncology Model1
1/0
9/2
02
11
1C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Radiation Oncology Model - Before Performance Year Start1
1/0
9/2
02
11
2C
on
fid
en
tia
l
After final rule publishes, updated
Case Mix and Historical Experience
Adjustments will be available here
If practice is eligible for low volume opt-out
option, they will see this text
Legal contacts will see a check box
at bottom of this text that must be selected
before start of performance year
Practice can view old Case Mix and
Historical Experience Adjustment data
here
This data can be put into Payment
Calculator on RO Model website to
estimate payments under RO Model
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Radiation Oncology (RO)
Quality Measures
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• RO Model qualifies as Advanced Alternative Payment Model (APM) and Merit-Based
Incentive Payment System(MIPS) APM
• Three Quality Payment Program (QPP) Tracks
1. Track One
− Professional and dual participants who comply with all RO requirements, including CEHRT
• CMS expects this track to qualify as both Advanced APM and MIPS APM
2. Track Two
− Professional and dual participants who comply with all RO requirements except for CEHRT
• CMS expects this track to qualify as MIPS APM only
3. Track Three
− All other RO participants and will not qualify as MIPS APM or Advanced APM
Quality Reporting1
1/0
9/2
02
11
4C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
RO Model does not require clinical and quality data reporting requirements
for Technical participants (except for Patient Experience)
Professional participants and Dual participants must:
• Submit biannual clinical data elements data for RO beneficiaries who
were treated for applicable cancer types and completed their RO episode
in preceding 6 months
• Clinical data elements data are reported in July for episodes completed
January 1 - June 30 and in January for episodes completed July 1 -
December 31
Clinical and Quality Data Reporting Requirements for Professional
Participants and Dual Participants
11
/09
/20
21
15
Con
fid
en
tia
l
RO Model Quality Measure
and Clinical Data Element
Collection and Submission
Guide and data reporting
templates are available on
RO Model website
UPDATE:
Requirement that participants
collect and submit quality
measures and clinical data
elements will be optional in PY1
(2022)
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• Quality measures for RO Model are:
• Oncology: Medical and Radiation - Plan of Care for Pain
• NQF #0383, CMS Quality ID #144
• Treatment Summary Communication – Radiation Oncology
• Preventive Care and Screening: Screening for Depression and Follow-Up Plan
• NQF #0418, CMS Quality ID #134
• Advance Care Plan
• NQF #0326, CMS Quality ID #047
• Professional, Technical and Dual participants must:
• Starting in Performance Year 3, results from selected patient experience
measures based on CAHPS Cancer Care Radiation Therapy survey will be
incorporated into Aggregate Quality Score (AQS) and applied to quality
withhold and patient experience withhold
− CMS will administer CAHPS Cancer Care Radiation Therapy survey, RO participants
do not need to contract with separate entity to administer survey
Clinical and Quality Data Reporting Requirements for
Professional Participants and Dual Participants
11
/09
/20
21
16
Con
fid
en
tia
l
Final CMS determinations
of Advanced APMs and
MIPS APMs for 2022
performance period will be
announced via QPP website
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Radiation Oncology (RO)
Coding and Billing
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• Bill for episodes
• SOE – modifier V1
• EOE – modifier V2
• Bill for excluded Episode services
• Use GB modifier
• Bill all covered services during 90-day episode
• No-pay data
• Bill/collect 20% patient responsibility
RO Billing Specifics1
1/0
9/2
02
11
8C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Cancer Types and Modalities
15 Cancer Types
• Anal Cancer
• Bladder Cancer
• Bone Metastases
• Brain Metastases
• Breast Cancer
• Cervical Cancer
• CNS Tumors
• Colorectal Cancer
• Head and Neck Cancer
• Lung Cancer
• Lymphoma
• Pancreatic Cancer
• Prostate Cancer
• Upper GI Cancer
• Uterine Cancer
11
/09
/20
21
19
Con
fid
en
tia
l
Modalities
• 3-Dimensional Conformal Radiotherapy (3DCRT)
• Intensity-Modulated Radiotherapy (IMRT)
• Stereotactic Radio Surgery (SRS)
• Stereotactic Body Radio Therapy (SBRT)
• Proton Beam Therapy (PBT)
• RO model does not include PBT that is furnished
toRO beneficiary participating in federally-
funded, multi-institution, randomized control
clinical trial for PBT
• Image-Guided Radiation Therapy (IGRT)
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• Receives RT services for at least 1 of 15 included cancer types
• Has traditional Medicare fee-for-service as primary payer
• Is eligible for Medicare Part A and enrolled in Medicare Part B
• NOT enrolled in Medicare health plan or Program of All-Inclusive Care for the Elderly plan
• NOT exercising Medicare hospice benefit
• NOT covered under United Mine Workers at time of episode
• NOT deceased prior to start of episode
• Part D coverage is not a requirement for beneficiary eligibility
• Beneficiaries enrolled in clinical trial for RT services (except Proton Beam Therapy) for which
Medicare pays routine costs would also be included in RO Model, if above also applies
Opt-Out
• Beneficiaries may not opt out of RO Model if they receive RT services from RO participant
• Beneficiaries can choose not to share their Medicare claims data with RO participants
RO Beneficiary Defined1
1/0
9/2
02
12
0C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• If practice has multiple locations that bill under same TIN, only those with site of service
addresses in an included ZIP Code will be RO participants
• Having one included ZIP Code does not automatically mean all locations are in the RO Model
− Billing address does not determine participation
• If organization furnishes RT services in various locations, only those furnishing included RT
services within participating ZIP Codes are RO participants
• However, historical experience and case mix adjustments are calculated from all locations that
furnish RT services under one TIN
Practice with Multiple Locations1
1/0
9/2
02
12
1C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Episode Services
Included Services
• Initial consultation (typically billed using
E&M service)
• Experimental and low volume treatments
(neutron beam, hyperthermia)
• General imaging not related to radiation
prep
• RT furnished in any setting other than a
HOPD or freestanding RT center
• Radiopharmaceuticals
• Intra-operative RT
• Brachytherapy services
*** When billing FFS, must attach modifier GB
to each service line11
/09
/20
21
22
Con
fid
en
tia
l
• Treatment planning
• Determining treatment modality, parts of the body
that must be radiated, and plan for RT (e.g., RT
Planning
• Technical preparation and special services
• Technical preparation to confirm radiation dosing is
accurate, machine is prepared, and treatment aids
are constructed (e.g., RT Aids)
• Treatment delivery
• Radiation delivered to patient in one or more
sessions (e.g., RT Delivery)
• Treatment management
• Patient monitoring and treatment adjusted according
to outcomes (e.g., RT Management x 5 Treatments)
Excluded Services (bill FFS)
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Professional or Dual Participant Billing Professional Component
for Excluded Modality (e.g., Brachytherapy) or Services
11
/09
/20
21
23
Con
fid
en
tia
l
Field Locators to Note:
FL 21: ICD-10 Diagnosis Code
FL 24A: Date(s) of Service
FL 24D: HCPCS Code & Modifier
FL 24E: Diagnosis pointer
FL 24F: Charges
FL 24G: Days or Units
FL 28: Total Charge
FL 32: Service Facility Location Information
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
RO Episode – 90 Days1
1/0
9/2
02
12
4C
on
fid
en
tia
l
Start of Episode (SOE) – CPT codes 77261, 77262, or 77263 are only codes that can be used to trigger RO episode
End of Episode (EOE)
• If RO beneficiary is not treated with RT from an RO participant within 28 days of initial treatment planning service,
then requirements for triggering an episode will not be met, and incomplete episode policy takes effect
• 28 days after an episode has ended is the “clean period” during which time an RO participant will bill RT services
furnished to RO beneficiary in accordance with Medicare fee-for-service rules
• If clinically appropriate, an RO participant may initiate another episode for same RO beneficiary
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• Reasons for incomplete episode
• Technical or Dual participant does not
furnish technical component (TC) to RO
beneficiary within 28 days following initial
RT treatment planning service
• Traditional Medicare stops being primary
payer for RO beneficiary at any point
during 90-day period, provided that RT
provider or RT supplier furnishes TC RT
service to RO beneficiary within 28 days
of initial treatment planning service
• RO beneficiary switches RT provider or
RT supplier before all RT services in
episode have been furnished
Incomplete Episode1
1/0
9/2
02
12
5C
on
fid
en
tia
l
• Incomplete episodes are reconciled to FFS
during annual reconciliation process• Except when RO beneficiary ceases to
have traditional FFS Medicare as their
primary payer at any time after initial
treatment planning service is furnished and
before date of service on claim with an RO
Model-specific HCPCS code and end-of-
episode (EOE) modifier, provided an RO
participant furnishes TC RT service to RO
beneficiary within 28 days of such initial
treatment planning service
• In this case, RO participant is owed
only first installment of episode
payment amount
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Episode Payments1
1/0
9/2
02
12
6C
on
fid
en
tia
l
Episode payments are split into 2 components:
• Professional component
• Technical component
Episode payments are made in 2 installments:
• 50% at start of episode
• 50% at end of episode (no sooner than day 28
of episode)
• RO episode is included in, and paid for under, RO Model if RO beneficiary dies after Technical
component of RO episode has been initiated, or if RO beneficiary elects Medicare hospice
benefit after initial treatment planning service, provided that Technical component is initiated
within 28 days following initial treatment planning service
• Each RO participant will receive both installments of episode payment under such
circumstances, regardless of whether RO beneficiary dies or elects Medicare hospice
benefit before relevant course of RT treatment has ended
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Episode Billing1
1/0
9/2
02
1C
on
fid
en
tia
l2
7
**Diagnosis and Cancer type must match SOE and EOE or it will be considered incorrect billing
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Episode Payment – National Base Rate (based on 2019 dollars)1
1/0
9/2
02
12
8C
on
fid
en
tia
l
Cancer Types RO Model-Specific Codes Professional or Technical National Base Rate
Anal Cancer M1072 Professional $3,104.11
Anal Cancer M1073 Technical $16,800.83
Bladder Cancer M1074 Professional $2,787.24
Bladder Cancer M1075 Technical $13,556.06
Bone Metastasis M1076 Professional $1,446.41
Bone Metastasis M1077 Technical $6,194.22
Brain Metastasis M1078 Professional $1,651.56
Brain Metastasis M1079 Technical $9,879.40
Breast Cancer M1080 Professional $2,059.59
Breast Cancer M1081 Technical $10,001.84
Excerpt - Handout
Table 75
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Professional and Technical Components: Example Claim for Dual Participant
Field Locators to Note:
FL 21: ICD-10 Diagnosis Code
FL 24A: Date(s) of Service - SOE
FL 24D: HCPCS Code & Modifier
FL 24E: Diagnosis pointer
FL 24F: Charges
FL 24G: Days or Units
FL 28: Total Charge
FL 32: Service Facility Location
Information
11
/09
/20
21
29
Con
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• In addition to SOE and EOE claims, all RO participants must submit RO Model encounter data on
no-pay claims for all included RT services identified on RO Model Packaged/Bundled HCPCS
Codes list within a given 90-day episode
• No other HCPCS codes can be included on claims with RO Model-specific HCPCS codes
(using V1 and V2 modifier)
• Encounter-like (no-pay) claims should be submitted after RO episode has been established with
adjudication of SOE claim
Encounter (no-pay) Claims1
1/0
9/2
02
13
0C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
1. Identify national base rate for cancer type
− Since 15 cancers are included, CMS will create 30 base rates using historical average cost for
episode of care based on FFS claims from 2017 to 2019
2. Apply trend factor to base rates to reflect current trends in payment and treatment pattern
changes
3. Apply geographic adjustments
4. Adjust base rates for each participant's historical experience and case mix history
5. Apply discount factor
− 3.5% for PC, 4.5% for TC
Pricing Process – 8 Steps1
1/0
9/2
02
13
1C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
6. Apply incorrect payment withhold, quality withhold and/or patient experience withhold
- Starting in PY1, incorrect payment withhold reserves money for reconciling duplicate or incomplete
episodes; it will be 1% of total episode payment for PC and TC
- There will be annual reconciliation process to determine if participants receive back full 1%, a portion
of it, or owe money to CMS
- Starting in PY2, quality withhold will hold back 2% of payment that participants can earn back based
on their performance on and reporting of quality
- Applies only to the professional component
- Starting in PY3, a 1% patient experience withhold will kick in for and will be based on scores from the
Cancer CAHPS for Radiation Therapy
7. Apply beneficiary coinsurance
- Beneficiaries have 20% coinsurance
8. Apply sequestration adjustment in accordance with applicable law
Pricing Process – 8 Steps (cont.)1
1/0
9/2
02
13
2C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Discounts and Withholds Professional Component Technical Component
Discount Rate 3.5% 4.5%
Incorrect Payment Withhold 1% 1%
Quality Withhold 2%
(UPDATE: Quality withhold will not be
applied in PY 1 since reporting is optional)
N/A
Patient Experience Withhold N/A 1% (beginning in PY3)
Discounts and Withholds1
1/0
9/2
02
13
3C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• Assign/identify Primary Point of Contact AND Legal contact
• Register for ROAP – need Model ID, TIN, Primary Point of Contact
• Educate revenue cycle team regarding billing requirements
• RO Model Specific HCPCS codes – List of M codes
• RO modifiers – V1, V2, GB
• Included beneficiaries
• Monitor Radiation Oncology website -https://innovation.cms.gov/innovation-models/radiation-oncology-
model
• Register for and attend scheduled webinars
− RO Model Clinical Data Elements and Quality Measures Reporting Requirements Webinar (November
16, 2021 - 3 pm EST)
− RO Model QPP, APM and MIPS Webinar (December)
Radiation Oncology Model – Major Takeaways1
1/0
9/2
02
13
4C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
InfoDive Reports
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Simulation Logic1
1/0
9/2
02
13
6C
on
fid
en
tia
l
• Builds an RO episode for every patient with treatment planning (CPTs 77261, 77262, 77263)
• Multiple episodes will exist for patients with multiple treatment planning dates
• Episodes will not overlap
• Uses the zip code of the location where the treatment planning is delivered to determine if the zip code
is in a CBSA covered by the model
• A cancer type is assigned using the diagnosis codes associated to the treatment planning code
• The number of days between planning and initial treatment to determine if the episode is incomplete
(>28 days)
• Assigns the National Base Rate for both professional and technical components based on the cancer
type
• Identify services that are included in the model and
• Assign the MPFS fee schedule value of the service based on the schedule in effect on the
date of service
• Determine if the service date was within 90 days of the treatment planning
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
• Reports simulating the Radiation Oncology model have been prepared for practices that subscribe to
InfoDive practice analytics.
• Reports can be found under the ‘Custom’ area
InfoDive Simulation of Radiation Oncology Model1
1/0
9/2
02
13
7C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Summary Report1
1/0
9/2
02
13
8C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Episode Level 1
1/0
9/2
02
13
9C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Episode Service Detail1
1/0
9/2
02
14
0C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Assistance with InfoDive reports – [email protected]
Cass Schaedig – [email protected]
Cindy Dunn – [email protected]
Contact Information1
1/0
9/2
02
14
1C
on
fid
en
tia
l
Intr
insiQ
Sp
ecia
lty S
olu
tio
ns
Q&A